MBHB Partner Andrew Williams Authors Article Entitled, “Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?”

McDonnell Boehnen Hulbert & Berghoff LLP partner Andrew W. Williams, Ph.D., authored an article entitled, “Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?” that appears in the June 10, 2015 online edition of BIOTechNOW. In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first time provided for biosimilar or interchangeable biological drug products.  But it was not until March 6, 2015, that the FDA approved the first biosimilar application – an application by Sandoz to market a version of Amgen’s NEUPOGEN^® (filgrastrim) biologic drug product.  Nevertheless, there is still a question as to when Sandoz will be able to begin selling its drug product, because the parties are still resolving the patent issues. View the article